Insider Sell: BioXcel Therapeutics
12:39AM ET 3/23/2023 MT NewswiresVimal Mehta, Director, Chief Executive Officer and President, on March 20, 2023, sold 64,500 shares in BioXcel Therapeutics (BTAI) for $1,223,313....
HC Wainwright Adjusts Price Target on BioXcel Therapeutics to $66 From $79, Keeps Buy Rating
7:25AM ET 3/21/2023 MT NewswiresBioXcel Therapeutics (BTAI) has an average rating of outperform and price targets ranging from $22 to $82, according to analysts polled by Capital IQ. (MT...
UBS Adjusts BioXcel Therapeutics Price Target to $48 From $52, Maintains Buy Rating
10:15AM ET 3/13/2023 MT NewswiresBioXcel Therapeutics (BTAI) has an average rating of Outperform and price targets ranging from $22 to $82, according to analysts polled by Capital IQ. (MT...
--Jefferies Downgrades BioXcel Therapeutics to Hold From Buy, Adjusts Price Target to $22 From $20
7:11AM ET 3/10/2023 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
BioXcel Therapeutics' Q4 Loss Widens
7:39AM ET 3/09/2023 MT NewswiresBioXcel Therapeutics (BTAI) reported a Q4 loss Thursday of $1.95 per share, wider than a loss of $0.93 a year earlier. Analysts polled by Capital IQ...
HC Wainwright Adjusts Price Target on BioXcel Therapeutics to $79 From $73, Maintains Buy Rating
9:22AM ET 2/21/2023 MT NewswiresBioXcel Therapeutics (BTAI) has an average buy rating and price target range of $20 to $82, according to analysts polled by Capital IQ. (MT Newswires...
UBS Adjusts BioXcel Therapeutics Price Target to $52 From $23, Maintains Buy Rating
9:47AM ET 2/15/2023 MT NewswiresBioXcel Therapeutics (BTAI) has an average rating of Buy and price targets ranging from $20 to $82, according to analysts polled by Capital IQ. (MT...
BioXcel Says Phase 2 Trial of Prostate Cancer Combination Therapy Achieved Primary Endpoint
3:44AM ET 2/14/2023 MT NewswiresBioXcel Therapeutics (BTAI) said late Monday its phase 2 trial testing the combination of BXCL701 and Merck's (MRK) Keytruda in castration-resistant...
--Mizuho Securities Adjusts Price Target on BioXcel Therapeutics to $38 From $24, Maintains Buy Rating
12:33PM ET 2/08/2023 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
BioXcel Executive Joins Karuna Therapeutics as Chief Commercial Officer
6:51AM ET 1/31/2023 MT NewswiresKaruna Therapeutics (KRTX) said Tuesday that it has named Will Kane chief commercial officer, effective Feb. 6. Kane has previously served as executive...